Antithrombin: A new look at the actions of a serine protease inhibitor

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 8, 2002, Pages 657-670

  Roemisch, J ^a,b   Gray, E ^c   Hoffmann, J N ^d   Wiedermann, C J ^e   Kalina, Uwe ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b Octapharma Pharmazeutika Produktions GmbH   (Austria)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anti coagulation; Anti inflammation; Antithrombin; Heparin interaction; Sepsis disseminated intravascular coagulation

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; CELL RECEPTOR; GLYCOPROTEIN; HEPARIN; LIPOPOLYSACCHARIDE; PLACEBO; PROSTACYCLIN; PROTEINASE; SERINE PROTEINASE INHIBITOR; SYNDECAN; THROMBIN;

ANGIOGENESIS; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; MEDIATOR RELEASE; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; WOUND HEALING;

ANIMALS; ANTITHROMBIN III; BLOOD COAGULATION; HUMANS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; SEPSIS; SERINE PROTEINASE INHIBITORS;

EID: 0036910608     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200212000-00001     Document Type: Review

References (106)

1. Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL. Antithrombin: The principal inhibitor of thrombin. Semin Thromb Hemost 1994; 20: 353-372.
2. Rosenberg JS, McKenna PW, Rosenberg RD. Inhibition of human factor IXa by human antithrombin. J Biol Chem 1975; 250: 8883-8888.
3. Stead N, Kaplan AP, Rosenberg RD. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 1976; 251: 6481-6488.
4. Damus PS, Hicks M. Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355-357.
5. Rao LVM, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces: Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-129.
6. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: New therapeutic implications. Semin Thromb Hemost 1998; 24: 27-32.
7. Justus AC, Roussev R, Norcross J, Faulk WP. Antithrombin binding by human umbilical vein endothelial cells: Effects of exogenous heparin. Thromb Res 1995; 79: 175-186.
8. Yamashiro K, Kiryu J, Tsujikawa A, Honjo M, Nonaka A, Miyamoto K, et al. Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2001; 42: 1553-1560.
9. Dunzendorfer S, Rabensteiner A, Kaneider N, Meierhofer C, Römisch J, Wiedermann CJ. Involvement of CXC-receptor-1 in antithrombin-induced neutrophil migration. In: Faist E (editor): Proceedings of the 5th World Congress on Trauma, Shock, Inflammation and Sepsis, Munich, Germany, 29 February-4 March 2000. Monduzzi Editore, Italy-MEDIMOND, USA; 2000. pp. 703-706.
10. Dunzendorfer S, Kaneider N, Rabensteiner A, Meierhofer C, Reinisch C, Römisch J, Wiedermann CJ. Cell-surface heparan sulfate proteoglycan-mediated regulation of neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-1085.
11. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 2001; 287: 42-46.
12. Gray E, Sourer P, Römisch J, Poole S. Antithrombin inhibits in vitro lipopolysaccharide induced procoagulant activity and cytokine production [abstract 579]. Shock 2000; 13: 147.
13. Hoffmann JN, Vollmar B, Roemisch J, Inthorn D, Schildberg FW, Menger MD. Antithrombin effects on endotoxin-induced microcirculatory disorders are mainly mediated by its interaction with microvascular endothelium. Crit Care Med 2002; 30: 218-225.
14. Kaneider N, Reinisch C, Dunzendorfer S, Römisch J, Wiedermann C. Syndecan-4 on human peripheral blood lymphocytes and monocytes mediates effects of antithrombin on chemotaxis. J Cell Sci 2002; 115: 227-236.
15. Sourer PJ, Thomas S, Hubbard AR, Poole S, Römisch J, Gray E. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29: 134-139.
16. Pulletz S, Lehmann C, Volk T, Schmutzler M, Ziemer S, Kox WJ, Scherer RU. Influence of heparin and hirudin on endothelial binding of antithrombin in experimental thrombinemia. Crit Care Med 2000; 28: 2881-2886.
17. Oelschläger C, Römisch J, Staubitz A, Stauss H, Leithäuser B, Tillmanns H, Hölschermann H. Antithrombin inhibits NF-KB signaling pathways in monocytes and endothelial cells in vitro. Blood 2002; 99: 4015-4020.
18. Iampietro R, Souter P, Römisch J, Poole S, Gray E. Antithrombin inhibits in vitro lipopolysaccharide induced interleukin-6 production by suppression of mRNA [abstract 344]. Intensive Care Med 2000; 26 (suppl 3): S302.
19. Horie S, Ishii H, Kazama M. Heparin-like glycosa-minoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990; 59: 895-904.
20. Hoffmann JN, Vollmar B, Laschke M, Inthorn D, Kaneider N, Dunzendorfer S, et al. Heparin antagonizes antithrombin-mediated inhibitory action on endotoxic microcirculatory dysfunction in vivo. Thromb Haemost 2002; 88: 242-252.
21. Carrell RW, Stein PE, Fermi G, Wardell MR. Biological implications of a 3 Å structure of dimeric antithrombin. Structure 1994; 2: 257-270.
22. Wu YI, Sheffield WP, Blajchman MA. Defining the heparin-binding domain of antithrombin. Blood Coagul Fibrinolysis 1994; 5: 83-95.
23. Swedenborg J. The mechanisms of action of alpha- and beta-isoforms of antithrombin. Blood Coagul Fibrinolysis 1998; 9 (suppl 3): S7-S10.
24. Roemisch J, Palkis S, Stauss H. Anticoagulant properties of antithrombin III-alpha and -beta in a TNF stimulated endothelial cell culture system [abstract 3332]. Blood 1998; 10 (suppl 1): page 82b.
25. Roemisch J, Doenges R, Stauss H, Inthron D, Mühlbayer D, Jochum M. Hoffmann JN. AT isoform proportion in plasmas of healthy subjects, septic patients and AT concentrates: A novel method of quantitation [abstract 345]. Pathophys Haemost Thromb 2002; 32: 143-150.
26. Fuhge P, Gratz P, Geiger H. Modern methods of the manufacture of coagulation factor concentrates. Transf Sci 1990; 11: 23S-33S.
27. Hoffmann DL. Purification and large-scale preparation of antithrombin III. Am J Med 1989; 87: 23S-26S.
28. Lebing WR, Hammond DJ, Wydick JE, Baumbach GA. A highly purified antithrombin III concentrate prepared from human plasma fraction IV-1 by affinity chromatography. Vox Sang 1994; 67: 117-124.
29. Hellstern P, Moberg U, Ekblad M, Anders CU, Faller B, Muller S. In vitro characterization of antithrombin III concentrates - A single-blind study. Haemostasis 1995; 25: 193-201.
30. Groener A, Nowak T, Roemisch J. Purity, activity, and virus safety of a pasteurized antithrombin concentrate. Semin Thromb Hemost 2002; 28 (suppl 1): 79-85.
31. Edmunds T, Van Patten SM, Pollock J, Hanso E, Bernasconi R, Higgins E, et al. Transgenically produced human antithrombin: Structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91: 4561-4571.
32. Lu W, Mant T, Levy JH, Bailey JM. Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg 2000; 90: 531-534.
33. Levy JH, Weisinger A, Ziomek CA, Echelard Y. Semin Thromb Hemost 2001; 27: 405-416.
34. Levy JH, Despotis GJ, Szlam F, Olson P, Meeker D, Weisinger A. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesia 2002; 96: 1095-1102.
35. Periti P. Current treatment of sepsis and endotoxaemia. Expert Opin Pharmacother 2000; 1: 1203-1217.
36. Baudo F, de Cataldo F. Antithrombin III concentrates in the treatment of sepsis and septic shock: Indications, limits and future prospects [in Italian]. Minerva Anestesiol 2000; 66 (suppl 1): 3-23.
37. Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998; 24: 33-44.
38. Mammen EF. The haematological manifestations of sepsis. J Antimicrob Chemother 1998; 41 (suppl A): 17-24.
39. Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu O. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 1998; 26: 2005-2009.
40. Opal SM. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 2000; 28 (suppl): S34-S37.
41. Reinisch C, Kaneider N, Rabensteiner A, Dunzendorfer S, Römisch J, Wiedermann C. Specific deactivation of monocyte and lymphocyte migration by AT concentrate [abstract 341]. Intensive Care Med 2000; 26 (suppl 3): S302.
42. Taylor FB Jr, Emerson TE Jr, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988; 26: 227-235.
43. Dickneite G, Pâques E-P. Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella. Thromb Haemost 1993; 69: 98-102
44. Kessler CM, Tang Z-C, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: Substantial reduction in mortality and morbidity. Blood 1997; 89: 4393-4401.
45. Dickneite G, Leithäuser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Arterioscler Thromb Vasc Biol 1999; 19: 1566-1572.
46. Dickneite G, Kroez M. Treatment of porcine sepsis with high-dose antithrombin III reduces tissue edema and effusion but does not increase risk for bleeding. Blood Coagul Fibrinolysis 2001; 12: 459-467.
47. Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999; 93: 157-164.
48. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998; 89: 233-241.
49. Okajima K. The role of antithrombin III in severe sepsis - Anticoagulation and beyond. Biomed Progr 1996; 9: 42-44.
50. Hoffman JN, Faist E. Coagulation inhibitor replacement during sepsis: Useless? Crit Care Med 2000; 28 (suppl): S74-S76.
51. Vincent J-L. New therapeutic implications of anti-coagulation mediator replacement in sepsis and acute respiratory distress syndrome. Crit Care Med 2000; 28 (suppl): S83-S85.
52. Fourrier F, Jordain M, Tournoys A. Clinical trial results with antithrombin III in sepsis. Crit Care Med 2000; 28 (suppl): S38-S43.
53. Thijs LG. Coagulation inhibitor replacement in sepsis is a potentially useful clinical approach. Crit Care Med 2000; 28 (suppl): S68-S73.
54. Fourrier F, Chopin C, Huart J-J, Runge I, Cavan C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882-888.
55. Inthorn D, Hoffmann JN, Hartl WH, Mühlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 1997; 8: 328-334.
56. Inthorn D, Hoffmann JN, Hartl WH, Mühlbayer D, Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock 1998; 10: 90-96.
57. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24: 336-342.
58. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antithrombin III in patients with severe sepsis: A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24: 663-672.
59. Opal SM. Antithrombin-III in the treatment of severe sepsis: The results of a phase III multicenter clinical trial. J Anasth Intensivbehandlung 2001; 46: 46-47.
60. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286: 1869-1878.
61. Knaub S, Keinecke H-O, Mescheder A, Heinrichs H. Antithrombin III in patients with severe sepsis - A clinical development plan. Ann Hematol 1998; 76 (suppl 1): A47. abstract.
62. Knaub S, Keinecke H-O, Juers M, Schindel F, Heinrichs H. Opal SM. High-dose antithrombin III in patients with severe sepsis - the Kybersept trial [abstract P523]. Thromb Haemost 2001; 86 (suppl 1). p523.
63. De Jonge E, van der Poll T, Kesecioglu J, Levi M. Anticoagulant factor concentrates in disseminated intravascular coagulation: Rationale for use and clinical experience. Semin Thromb Hemost 2001; 27: 667-674.
64. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-56.
65. Opal S, Thijs L, Cavaillon JM, Cohen J, Fourrier F. Roundtable I: Relationship between coagulation and inflammatory processes. Crit Care Med 2000; 28 (9 suppl): S81-S82.
66. Freeman BD, Buchman TG. Coagulation inhibitors in the treatment of sepsis. Expert Opin Investig Drugs 2002; 11: 69-74.
67. Bernard G, Vincent J, Laterre P, LaRosa SP, Dhainaut JP, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
68. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28 (9 suppl): S31-S33.
69. Opal SM. Clinical impact of novel anticoagulation strategies in sepsis. Curr Opin Crit Care 2001; 7: 347-353.
70. Mazzucconi MG, Gugliotta L, Leone G, Dragoni F, Belmonte MM, De Stefano V, et al. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase: A GIMEMA study. Blood Coagul Fibrinolysis 1994; 5: 23-28.
71. Grip L, Blombäck M, Egberg N, Olsson A, Svane R, Velander M. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris: A controlled randomized double-blind pilot study. Eur Heart J 1997; 18: 443-449.
72. Becker BF, Heindl B, Kupatt C, Zahler S. Hauptvortrag: Endothelfunktion und hämostase [Endothelial function and hemostasis]. Z Kardiol 2000; 89: 160-167.
73. Senden NHM, Jeunhomme TMAA, Heemskerk JWM, Wagenvoord R, van't Veer C, Hemker HC, et al. Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J Immunol 1998; 161: 4318-4324.
74. Beviliacqua MP, Gimbrone MA. Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost 1987; 13: 425-433.
75. Osterud B. Tissue-factor expression by monocytes: Regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998; 9 (suppl 1): S9-S14.
76. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Boold-borne tissue-factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315.
77. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999; 96: 11023-11027.
78. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068.
79. Chen J, IshiiM, Wang L, Ishii K, Coughlin SR. Thrombin receptor activation: Confirmation of the intramolecular tethered ligand hypothesis and discovery of an alternative intermoleculr ligand mode. J Biol Chem 1994; 269: 16041-16045.
80. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, Brass LF. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 2000; 275: 13502-13509.
81. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 2001; 86: 298-307.
82. Ishii K, Chen J, Ishii M, Koch WJ, Freedman NJ, Lefkowitz RJ, Coughlin SR. Inhibition of receptor signaling by a G protein-coupled receptor kinase. J Biol Chem 1994; 269: 1125-1130.
83. Hein L, Ishii K, Coughlin SR, Kobilka BK. Intracellular targeting and trafficking of thrombin receptors: A novel mechanism for resensitization of a G protein-coupled receptor. J Biol Chem 1994; 269: 27719-27726.
84. Esmon C. The protein C pathway. Crit Care Med 2000; 28 (suppl): S44-S48.
85. Opal SM. Phylogenetic and functional relationships between coagulation and the innate immune response. Crit Care Med 2000; 28 (suppl): S77-S80.
86. Ludwicka-Bradley A, Tourkina E, Suzuki S, Tyson E, Bonner M, Fenton JW, et al. Thrombin upregulates interleukin-8 in lung fibroblasts via cleavage of proteolytically activated receptor-I and protein kinase C-γ activation. Am J Respir Cell Mol Biol 2000; 22: 235-243.
87. Rabiet MJ, Plantier JL, Dejana E. Thrombin-induced endothelial cell dysfunction. Br Med Bull 1994; 50: 936-945.
88. Kaur J, Woodman RC, Ostrovsky L, Kubes P. Selective recruitment of neutrophils and lymphocytes by thrombin: A role for NF-kappaB. Am J Physiol Heart Circ Physiol 2001; 281: H784-H795.
89. Seegers WH. Antithrombin III: Theory and clinical applications: H. P. Smith Memorial Lecture. Am J Clin Pathol 1978; 69: 299-359.
90. Uchiba M, Okajima K. Antithrombin does not directly promote the endothelial production of prostacyclin in cultured endothelial cells. Thromb Haemost 2001; 86: 722-723.
91. Schobersberger W, Lercher A, Kountchev J, Römisch J, Margreiter J, Fürhapter Ch, et al. High AT concentrations release prostacyclin in human dermal microvascular cells (HDMEC) [abstract 339]. Intensive Care Med 2000; 26 (suppl 3): S301.
92. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997; 96: 2302-2310.
93. Nevière R, Tournoys A, Mordon S, Marechal X, Song FL, Jourdain M, et al. Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats. Shock 2001; 15: 220-225.
94. Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol 2000; 279: C98-C107.
95. Hoffmann JN, Vollmar B, Inthorn D, Schildberg FW, Menger MD. The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/endothelial cell interaction and microvascular perfusion failure. Shock 2001; 14: 528-534.
96. Yamashiro K, Kiryu J, Tsujikawa A, Honjo M, Nonaka A, Miyamoto K, et al. Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2001; 42: 1553-1560.
97. Woods A. Syndecans: Transmembrane modulators of adhesion and matrix assembly. J Clin Invest 2001; 107: 935-941.
98. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophysical Res Commun 1989; 163: 1404-1411.
99. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombon, heparin, and heparan sulfate. Crit Care Med 2002; 30 (5 suppl): S325-S331.
100. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin thrombin. Science 1999; 285: 1926-1928.
101. Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Kaine RM, et al. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152: 399-411.
102. Pahl MV, Vaziri ND, Oveisi F, Wang J, Ding Y. Antithrombin III inhibits mesangial cell proliferation. J Am Soc Nephrol 1996; 7: 2249-2253.
103. Kisker O, Onizuka S, Banyard J Komiyama T, Becker CM, Achilles EG, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 2001; 61: 7298-7304.
104. Larsson H, Sjöblom T, Dixelius J. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000; 60: 6723-6729.
105. Larsson H, Åkerud P, Nordling K, Ostman A, Ylinenjarvi K, Bjork I, et al. Novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J Biol Chem 2001; 276: 11996-12002.
106. Gray E, Roemisch J, Robinson J. Different antithrombin preparations, isoforms and fractions have different actions on growth factor-induced responses of HUVECs [abstract P1234]. Thromb Haemost 2001; 86(suppl 1). p152.